Aerocrine

Press release
2 October, 2007

Aerocrine submits 510(k) filing for NIOX MINO® in the U.S.

SOLNA – October 2, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announced that it has submitted a 510(k) application for marketing clearance to the U.S. Food & Drug Administration (FDA) for its NIOX MINO® device.

NIOX MINO® is the world's first hand-held non-invasive device to measure the concentration of nitric oxide in exhaled human breath (FE_{NO}). Nitric oxide is a marker for airway inflammation originally discovered by Aerocrine's founders. Today, FE_{NO} measurement is acknowledged in the scientific literature to have clinical relevance for the control of inflammatory airway disorders such as asthma. Evaluation of FE_{NO} measurements may constitute an important part of a disease management strategy to improve care of patients with inflammatory airway disorders.

"We are now looking forward to co-operating with the FDA during its review process for NIOX MINO®", says Paul de Potocki, CEO of Aerocrine.

For more information, contact:

Paul de Potocki, CEO, phone: +46 8 629 0782

About Aerocrine

Aerocrine AB is a clinically based medical technology corporation dedicated to improved asthma management and care. Aerocrine was listed on the Stockholm Stock Exchange on 15 June, 2007. The company is marketing NIOX® Flex on a worldwide basis and is also marketing NIOX MINO®, representing a new generation of hand-held devices, in Europe. Both products are tailored for rapid, non-invasive control of the inflammatory status in the airways and may play a critical role for optimized asthma care and disease control.
Aerocrine is located in Sweden with wholly owned subsidiaries in the US, UK and Germany.